Andromeda Biotech's Unattributed VC Round

Andromeda Biotech raised a round of funding on June 14, 2007. Investors include Clal Biotechnology Industries.

Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. The company's lead product, DiaPep277 is currently in Phase III clinical trials for treating type 1 …

Articles about Andromeda Biotech's Unattributed VC Round: